Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 889-901

  Jobson, Andrew G ^a,d   Willmore, Elaine ^a   Tilby, Michael J ^b   Mistry, Prakash ^c   Charlton, Peter ^c   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dual inhibitor; TARDIS assay; Topoisomerase I; Topoisomerase II

Indexed keywords

4 METHOXY BENZO[A]PHENAZINE 11 CARBOXYLIC ACID (2 DIMETHYLAMINO 1 METHYLETHYL)AMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HISTONE H2AX; PHENAZINE DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; XR 11576; XR 5944;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONFORMATION; DNA DAMAGE; DNA REPAIR; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; HUMANS; IMMUNOASSAY; K562 CELLS; PHENAZINES;

EID: 61449149520     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0812-9     Document Type: Article

References (41)

1. C Arnaudeau C Lundin T Helleday 2001 DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells J Mol Biol 307 1235 1245
2. JM Barret D Montaudon C Etievant D Perrin A Kruczynski J Robert BT Hill 2000 Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II Anticancer Res 20 4557 4562
3. LR Barrows JA Holden M Anderson P D'Arpa 1998 The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication Mutat Res 408 103 110
4. M Binaschi G Capranico L Dal Bo F Zunino 1997 Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity Mol Pharmacol 51 1053 1059
5. DJ Bridewell GJ Finlay BC Baguley 1999 Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II Cancer Chemother Pharmacol 43 302 308
6. SA Byers B Schafer DS Sappal J Brown DH Price 2005 The antiproliferative agent MLN944 preferentially inhibits transcription Mol Cancer Ther 4 1260 1267
7. JA Byl JM Fortune DA Burden JL Nitiss T Utsugi Y Yamada N Osheroff 1999 DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement Biochemistry 38 15573 15579
8. AY Chen LF Liu 1994 DNA topoisomerases: essential enzymes and lethal targets Annu Rev Pharmacol Toxicol 34 191 218
9. J Dai C Punchihewa P Mistry AT Ooi D Yang 2004 Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug J Biol Chem 279 46096 46103
10. MJ de Jonge S Kaye J Verweij C Brock S Reade M Scurr L van Doorn C Verheij W Loos C Brindley P Mistry M Cooper I Judson 2004 Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459 1465
11. F Di Nicolantonio LA Knight S Di Palma S Sharma PA Whitehouse SJ Mercer PA Charlton D Norris IA Cree 2004 Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors Anticancer Drugs 15 849 860
12. F Di Nicolantonio LA Knight PA Whitehouse SJ Mercer S Sharma PA Charlton D Norris IA Cree 2004 The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples Mol Cancer Ther 3 1631 1637
13. GJ Finlay JF Riou BC Baguley 1996 From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives Eur J Cancer 32A 708 714
14. JM Fortune L Velea DE Graves T Utsugi Y Yamada N Osheroff 1999 DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition Biochemistry 38 15580 15586
15. AJ Frank MJ Tilby 2003 Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation Exp Cell Res 283 127 134
16. AJ Frank SJ Proctor MJ Tilby 1996 Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells Blood 88 977 984
17. SM Harris P Mistry C Freathy JL Brown PA Charlton 2005 Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines Br J Cancer 92 722 728
18. SM Harris JA Scott JL Brown PA Charlton P Mistry 2005 Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma Anticancer Drugs 16 945 951
19. YH Hsiang LF Liu 1988 Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin Cancer Res 48 1722 1726
20. LH Jensen A Renodon-Corniere KC Nitiss BT Hill JL Nitiss PB Jensen M Sehested 2003 A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha Biochem Pharmacol 66 623 631
21. LJ Lewis P Mistry PA Charlton H Thomas HM Coley 2007 Mode of action of the novel phenazine anticancer agents XR11576 and XR5944 Anticancer Drugs 18 139 148
22. LF Liu TC Rowe L Yang KM Tewey GL Chen 1983 Cleavage of DNA by mammalian DNA topoisomerase II J Biol Chem 258 15365 15370
23. P Mistry AJ Stewart W Dangerfield M Baker C Liddle D Bootle B Kofler D Laurie WA Denny B Baguley PA Charlton 2002 In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II Anticancer Drugs 13 15 28
24. MT Muller 1983 Nucleosomes contain DNA binding proteins that resist dissociation by sodium dodecyl sulfate Biochem Biophys Res Commun 114 99 106
25. K Padget R Carr AD Pearson MJ Tilby CA Austin 2000 Camptothecin- stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining) Biochem Pharmacol 59 629 638
26. K Padget A Stewart P Charlton MJ Tilby CA Austin 2000 An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells Biochem Pharmacol 60 817 821
27. E Pastwa E Ciesielska MK Piestrzeniewicz WA Denny M Gniazdowski L Szmigiero 1998 Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide (DACA) and its analogues Biochem Pharmacol 56 351 359
28. D Perrin B van Hille JM Barret A Kruczynski C Etievant T Imbert BT Hill 2000 F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action Biochem Pharmacol 59 807 819
29. C Punchihewa A De Alba N Sidell D Yang 2007 XR5944: a potent inhibitor of estrogen receptors Mol Cancer Ther 6 213 219
30. VA Rao K Agama S Holbeck Y Pommier 2007 Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage Cancer Res 67 9971 9979
31. EP Rogakou DR Pilch AH Orr VS Ivanova WM Bonner 1998 DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 5858 5868
32. TC Rowe D Grabowski R Ganapathi 2001 Isolation of covalent enzyme-DNA complexes Methods Mol Biol 95 129 135
33. DS Sappal AK McClendon JA Fleming V Thoroddsen K Connolly C Reimer RK Blackman CE Bulawa N Osheroff P Charlton LA Rudolph-Owen 2004 Biological characterization of MLN944: a potent DNA binding agent Mol Cancer Ther 3 47 58
34. DA Scudiero RH Shoemaker KD Paull A Monks S Tierney TH Nofziger MJ Currens D Seniff MR Boyd 1988 Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res 48 4827 4833
35. O Sordet QA Khan Y Pommier 2004 Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction Cell Cycle 3 1095 1097
36. AJ Stewart P Mistry W Dangerfield D Bootle M Baker B Kofler S Okiji BC Baguley WA Denny PA Charlton 2001 Antitumor activity of XR5944, a novel and potent topoisomerase poison Anticancer Drugs 12 359 367
37. T Utsugi K Aoyagi T Asao S Okazaki Y Aoyagi M Sano K Wierzba Y Yamada 1997 Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II Jpn J Cancer Res 88 992 1002
38. W Verborg H Thomas D Bissett J Waterfall J Steiner M Cooper EM Rankin 2007 First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action Br J Cancer 97 844 850
39. JC Wang 1996 DNA topoisomerases Annu Rev Biochem 65 635 692
40. E Willmore AJ Frank K Padget MJ Tilby CA Austin 1998 Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique Mol Pharmacol 54 78 85
41. LA Zwelling M Hinds D Chan J Mayes KL Sie E Parker L Silberman A Radcliffe M Beran M Blick 1989 Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II J Biol Chem 264 16411 16420